Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 1101 to 1125 of 1146 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
662 occurrence Translocation, Genetic (MESH:D014178) 1253: MLL chromosomal translocation
20 decreased transmission of nerve impulse (GO:0019226) motor neuron (CL:0000100) 1267: Decrease, Ecdysis motor program activity
957 occurrence transmission of virus (GO:0019089) 2194: Influenza A Virus (IAV) shedding and transmission
124 decreased transport (GO:0006810) bile salt export pump (PR:000003549) 41: Inhibition, Bile Salt Export Pump (ABCB11)
505 increased transport (GO:0006810) thyroxine (CHEBI:30660) 960: Increased, Uptake of thyroxine into tissue
586 decreased transport (GO:0006810) nutrient (CHEBI:33284) 1132: Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal
608 increased transport (GO:0006810) thyroid hormone (CHEBI:60311) 1158: Increased, Hepatic thyroid hormone uptake/transport
636 decreased transport (GO:0006810) sodium(1+) (CHEBI:29101) 1176: Decreased, sodium conductance 2
637 decreased transport (GO:0006810) gamma-aminobutyric acid (CHEBI:16865) 1179: Decreased, GABA release
246 increased triglyceride biosynthetic process (GO:0019432) triglyceride (CHEBI:17855) 454: Increased, Triglyceride formation
372 increased tubulin binding (GO:0015631) tubulin (PR:000028799) 718: Binding, Tubulin
833 increased tumor necrosis factor secretion (GO:1990774) tumor necrosis factor alpha (PR:000000134) 1868: Hyperinflammation
787 decreased type I interferon signaling pathway (GO:0060337) signalling molecule (CHEBI:62488) None
878 decreased type I interferon signaling pathway (GO:0060337) interferon alpha (PR:000024938) 1901: Interferon-I antiviral response, antagonized by SARS-CoV-2
879 decreased type I interferon signaling pathway (GO:0060337) interferon beta (PR:000024939) 1901: Interferon-I antiviral response, antagonized by SARS-CoV-2
675 increased unsaturated fatty acid biosynthetic process (GO:0006636) unsaturated fatty acid (CHEBI:27208) 1285: Up Regulation, Unsaturated fatty acid
600 increased vascular calcification (MESH:D061205) vasculature (UBERON:0002049) 1151: Osteoporosis and vascular calcification, Bone deterioration
217 decreased vascular endothelial growth factor receptor 2 binding (GO:0043184) vascular endothelial growth factor receptor 2 (PR:000002112) 305: Inhibition, VegfR2
218 decreased vascular endothelial growth factor receptor 2 binding (GO:0043184) vascular endothelial growth factor receptor 1 (PR:000007563) 305: Inhibition, VegfR2
784 increased vascular inflammation (MP:0001863) 1867: Bradykinin system, hyperactivated
783 increased vasodilation (GO:0042311) 1867: Bradykinin system, hyperactivated
490 abnormal vasodilation (GO:0042311) blood vessel (UBERON:0001981) 937: KE7 : Impaired, Vasodilation
759 increased Venous thrombosis (HP:0004936) platelet (CL:0000233) 1846: Thrombosis and Disseminated Intravascular Coagulation
945 occurrence vesicle targeting, plasma membrane to endosome (GO:0048201) None
964 decreased viable offspring quantity (VT:1000181) 2147: Decreased, Viable Offspring